Business

Eli Lilly still hopeful on Alzheimer’s drug

Lilly’s Alzheimer’s drug is the second this year to fail; the other was from Pfizer and Johnson & Johnson.

Associated Press/File 2012

Lilly’s Alzheimer’s drug is the second this year to fail; the other was from Pfizer and Johnson & Johnson.

Advertisement

Eli Lilly & Co., still hopeful about an experimental Alzheimer’s drug despite two disappointing studies, said it will do another one, probably in the third quarter of 2013 and focusing on patients with mild Alzheimer’s. This year, two clinical trials showed solanezumab did not significantly improve either the cognition or daily functioning of people with mild and moderate forms of the disease. But when those with mild Alzheimer’s were separated out, the drug was shown to significantly slow their decline in cognition.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com